文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

MRI 放射组学预测同步放化疗或单纯同步放化疗后辅助化疗的局部晚期宫颈癌患者总生存期。

MRI radiomics in overall survival prediction of local advanced cervical cancer patients tread by adjuvant chemotherapy following concurrent chemoradiotherapy or concurrent chemoradiotherapy alone.

机构信息

Institute of Medical Technology, Peking University Health Science Center, China; Department of Radiation Oncology, Peking University Third Hospital, China.

Department of Radiation Oncology, Peking University Third Hospital, China.

出版信息

Magn Reson Imaging. 2022 Sep;91:81-90. doi: 10.1016/j.mri.2022.05.019. Epub 2022 May 27.


DOI:10.1016/j.mri.2022.05.019
PMID:35636572
Abstract

OBJECTIVES: To build radiomics based OS prediction tools for local advanced cervical cancer (LACC) patients treated by concurrent chemoradiotherapy (CCRT) alone or followed by adjuvant chemotherapy (ACT). And, to construct adjuvant chemotherapy decision aid. METHODS: 83 patients treated by ACT following CCRT and 47 patients treated by CCRT were included in the ACT cohort and non-ACT cohort. Radiomics features extracted from primary tumor area of T2-weighted MRI. Two radiomics models were built for ACT and non-ACT cohort in prediction of 3 years overall survival (OS). Elastic Net Regression was applied to the the ACT cohort, meanwhile least absolute shrinkage and selection operator plus support vector machine was applied to the non-ACT cohort. Cox regression models was used in clinical features selection and OS predicting nomograms building. RESULT: The two radiomics models predicted the 3 years OS of two cohorts. The receiver operator characteristics analysis was used to evaluate the 3 years OS prediction performance of the two radiomics models. The area under the curve of ACT and non-ACT cohort model were 0.832 and 0.879, respectively. Patients were stratified into low-risk group and high-risk group determined by radiomics models and nomograms, respectively. And, the low-risk group patients present significantly increased OS, progression-free survival, local regional control, and metastasis free survival compare with high-risk group (P < 0.05). Meanwhile the prognosis prediction performance of radiomics model and nomogram is superior to the prognosis prediction performance of Figo stage. CONCLUSION: The two radiomics model and the two nomograms is a prognosis predictor of LACC patients treated by CCRT alone or followed by ACT.

摘要

目的:建立基于放射组学的局部晚期宫颈癌(LACC)患者同步放化疗(CCRT)后接受辅助化疗(ACT)或不接受辅助化疗的生存预测工具,并构建辅助化疗决策辅助工具。

方法:将 83 例接受 ACT 治疗的患者和 47 例接受 CCRT 治疗的患者分别纳入 ACT 组和非 ACT 组。从 T2 加权 MRI 的原发肿瘤区域提取放射组学特征。使用弹性网络回归建立 ACT 组和非 ACT 组的放射组学模型,用于预测 3 年总生存率(OS)。最小绝对值收缩和选择算子加支持向量机应用于非 ACT 组。Cox 回归模型用于临床特征选择和 OS 预测列线图的构建。

结果:两个放射组学模型预测了两个队列的 3 年 OS。通过接受者操作特征分析评估两个放射组学模型的 3 年 OS 预测性能。ACT 和非 ACT 队列模型的曲线下面积分别为 0.832 和 0.879。根据放射组学模型和列线图将患者分为低危组和高危组。低危组患者的 OS、无进展生存、局部区域控制和无转移生存明显高于高危组(P<0.05)。同时,放射组学模型和列线图的预后预测性能优于 FIGO 分期。

结论:两个放射组学模型和两个列线图是预测 LACC 患者单纯 CCRT 或 CCRT 后接受 ACT 治疗的预后指标。

相似文献

[1]
MRI radiomics in overall survival prediction of local advanced cervical cancer patients tread by adjuvant chemotherapy following concurrent chemoradiotherapy or concurrent chemoradiotherapy alone.

Magn Reson Imaging. 2022-9

[2]
Development and validation of a F-FDG PET/CT radiomics nomogram for predicting progression free survival in locally advanced cervical cancer: a retrospective multicenter study.

BMC Cancer. 2024-1-30

[3]
MRI-based radiomics value for predicting the survival of patients with locally advanced cervical squamous cell cancer treated with concurrent chemoradiotherapy.

Cancer Imaging. 2022-7-16

[4]
Nomogram for Predicting Survival in Locally Advanced Cervical Cancer with Concurrent Chemoradiotherapy plus or Not Adjuvant Chemotherapy: A Retrospective Analysis Based on 2018 FIGO Staging.

Cancer Biother Radiopharm. 2024-11

[5]
Nomograms Combining Clinical and Imaging Parameters to Predict Recurrence and Disease-free Survival After Concurrent Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer.

Acad Radiol. 2023-3

[6]
A Multi-Institutional Retrospective Analysis of Oncologic Outcomes for Patients With Locally Advanced Cervical Cancer Undergoing Platinum-Based Adjuvant Chemotherapy After Concurrent Chemoradiotherapy.

Cancer Control. 2021

[7]
Machine learning-based radiomics for predicting outcomes in cervical cancer patients undergoing concurrent chemoradiotherapy.

Comput Biol Med. 2024-7

[8]
Added-value of dynamic contrast-enhanced MRI on prediction of tumor recurrence in locally advanced cervical cancer treated with chemoradiotherapy.

Eur Radiol. 2022-4

[9]
IVIM-DWI and MRI-based radiomics in cervical cancer: Prediction of concurrent chemoradiotherapy sensitivity in combination with clinical prognostic factors.

Magn Reson Imaging. 2022-9

[10]
Role of adjuvant chemotherapy after concurrent chemoradiotherapy in patients with locally advanced cervical cancer.

Future Oncol. 2022-5

引用本文的文献

[1]
Associations between MRI radiomics analysis and tumor-micro milieu in uterine cervical cancer.

J Cancer Res Clin Oncol. 2025-7-21

[2]
MRI delta radiomics during chemoradiotherapy for prognostication in locally advanced cervical cancer.

BMC Cancer. 2025-1-22

[3]
Automatic knee osteoarthritis severity grading based on X-ray images using a hierarchical classification method.

Arthritis Res Ther. 2024-11-18

[4]
Artificial Intelligence in Obstetric and Gynecological MR Imaging.

Magn Reson Med Sci. 2024-10-29

[5]
MRI radiomics and nutritional-inflammatory biomarkers: a powerful combination for predicting progression-free survival in cervical cancer patients undergoing concurrent chemoradiotherapy.

Cancer Imaging. 2024-10-24

[6]
Development and validation of a F-FDG PET/CT radiomics nomogram for predicting progression free survival in locally advanced cervical cancer: a retrospective multicenter study.

BMC Cancer. 2024-1-30

[7]
Response Assessment of Primary Liver Tumors to Novel Therapies: an Imaging Perspective.

J Gastrointest Surg. 2023-10

[8]
Frontiers and hotspots of F-FDG PET/CT radiomics: A bibliometric analysis of the published literature.

Front Oncol. 2022-9-13

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索